Feb 27, 2026 12:29PM
Feb 12, 2026 08:00AM
Feb 12, 2026 08:00AM
Nov 7, 2025 08:00AM
Nov 3, 2025 08:00AM
Oct 28, 2025 08:00AM
Oct 17, 2025 12:10PM ORYZON receives FDA feedback on phase III borderline personality disorder trial
Oct 17, 2025 12:08PM
Aug 25, 2025 08:00AM
Jul 30, 2025 08:00AM
Jul 21, 2025 08:00AM
Jul 14, 2025 08:00AM
Jun 25, 2025 08:00AM
Jun 23, 2025 08:00AM ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
Jun 17, 2025 08:00AM
May 27, 2025 08:00AM
May 12, 2025 08:00AM
May 8, 2025 08:00AM
Apr 24, 2025 08:00AM
Apr 21, 2025 08:00AM
Mar 14, 2025 08:00AM ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Mar 5, 2025 08:00AM
Mar 3, 2025 08:00AM
Feb 27, 2025 04:03PM
Feb 14, 2025 08:00AM
Jan 10, 2025 08:00AM
Dec 2, 2024 08:00AM
Oct 24, 2024 12:08PM ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
Oct 1, 2024 07:00AM
Sep 23, 2024 08:00AM
Sep 11, 2024 12:07PM
Sep 9, 2024 08:00AM
Sep 3, 2024 08:00AM
Aug 29, 2024 08:14AM
Jul 31, 2024 08:32AM ORYZON reports financial results and corporate update for half-year ending June 30, 2024
Jul 8, 2024 08:00AM
Jun 26, 2024 08:00AM
Jun 14, 2024 08:00AM
Jun 3, 2024 08:00AM
May 30, 2024 08:00AM
May 9, 2024 08:00AM
May 6, 2024 12:03PM ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
Apr 22, 2024 08:00AM
Apr 8, 2024 08:00AM
Apr 5, 2024 08:00AM
Feb 26, 2024 02:28PM
Feb 5, 2024 08:00AM
Jan 19, 2024 08:00AM
Jan 5, 2024 03:47PM ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
Nov 7, 2023 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All